{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:13:22Z","timestamp":1788300802151,"version":"build-2803163510"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004572","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004572","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128989","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:20:24Z","timestamp":1785738024000},"page":"128989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in clinical immunogenicity evaluation of influenza vaccines"],"prefix":"10.1016","volume":"89","author":[{"given":"Nan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziye","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10127","key":"10.1016\/j.vaccine.2026.128989_bb0005","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128989_bb0010","doi-asserted-by":"crossref","first-page":"e0002524","DOI":"10.1128\/cmr.00025-24","article-title":"Recent advances in the influenza virus vaccine landscape: a comprehensive overview of technologies and trials","volume":"37","author":"Clark","year":"2024","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128989_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13060620","article-title":"Production and immune response against pandemic influenza candidate vaccines as preparedness against the circulating H5N1 influenza viruses","volume":"13","author":"Lee Ho","year":"2025","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0020","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1186\/s12967-024-05676-9","article-title":"Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis","volume":"22","author":"Garai","year":"2024","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128989_bb0025","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00317-26","article-title":"Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines","volume":"100","author":"Loes","year":"2026","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128989_bb0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1128\/jcm.26.2.333-337.1988","article-title":"Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection","volume":"26","author":"Harmon","year":"1988","journal-title":"J Clin Microbiol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128989_bb0035","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/21645515.2020.1721223","article-title":"Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products","volume":"16","author":"Lai","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128989_bb0040","author":"Pharmaceutical Technology"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.128989_bb0045","article-title":"P-1438. A safety and immunogenicity study of Novavax\u2019s COVID-influenza combination and stand-alone influenza vaccines in adults 65 years and older","volume":"13","author":"Bennett","year":"2026","journal-title":"Open Forum Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128989_bb0050","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1001\/jama.2025.5646","article-title":"Immunogenicity and safety of influenza and COVID-19 multicomponent vaccine in adults \u226550 years: a randomized clinical trial","volume":"333","author":"Rudman Spergel","year":"2025","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128989_bb0055","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.4049\/jimmunol.1202790","article-title":"Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine","volume":"190","author":"Sl\u00fctter","year":"2013","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128989_bb0060","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00567-21","article-title":"Assay harmonization and use of biological standards to improve the reproducibility of the hemagglutination inhibition assay: a FLUCOP collaborative study","volume":"6","author":"Waldock","year":"2021","journal-title":"mSphere"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128989_bb0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/irv.12445","article-title":"Workshop report: immunoassay standardisation for \u201cuniversal\u201d influenza vaccines","volume":"11","author":"Pavlova","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128989_bb0070","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41579-021-00642-4","article-title":"Influenza lineage extinction during the COVID-19 pandemic?","volume":"19","author":"Koutsakos","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.128989_bb0075","first-page":"521","article-title":"Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season","volume":"98","year":"2023","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128989_bb0080","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.929572","article-title":"Immunogenicity of split inactivated quadrivalent influenza vaccine in adults with obesity in the 2017\/2018 season","volume":"27","author":"Jagielska","year":"2021","journal-title":"Med Sci Monit"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128989_bb0085","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.vaccine.2018.11.074","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35\u00a0months: a multi-season randomised placebo-controlled trial in the northern and southern hemispheres","volume":"37","author":"Pepin","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40794-024-00228-x","article-title":"A post-marketing study to evaluate the safety and immunogenicity of a quadrivalent influenza split-virion vaccine in elderly people aged 60 years and older","volume":"10","author":"Kou","year":"2024","journal-title":"Trop Dis Travel Med Vaccines"},{"issue":"27","key":"10.1016\/j.vaccine.2026.128989_bb0095","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1016\/j.vaccine.2021.05.001","article-title":"Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged \u2265 65 years","volume":"39","author":"Kim","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-199815010-00001","article-title":"Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature","volume":"15","author":"Beyer","year":"1998","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128989_bb0105","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/biot.201400438","article-title":"The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors","volume":"10","author":"Felberbaum","year":"2015","journal-title":"Biotechnol J"},{"issue":"25","key":"10.1016\/j.vaccine.2026.128989_bb0110","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older","volume":"376","author":"Dunkle","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128989_bb0115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025759118","article-title":"A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge","volume":"118","author":"Sia","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128989_bb0120","article-title":"Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine","volume":"5","author":"Sia","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1473-3099(21)00192-4","article-title":"Comparison of the safety and immunogenicity of a novel matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial","volume":"22","author":"Shinde","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0130","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2026.2638828","article-title":"Safety of Matrix-M-adjuvanted COVID-19, seasonal influenza, combination influenza-COVID-19, and malaria vaccines: a review of the evidence","volume":"25","author":"Fix","year":"2026","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128989_bb0135","article-title":"Adjuvanted recombinant hemagglutinin vaccine provides durable and broad-spectrum immunogenicity in mice","volume":"13","author":"Yu","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"38","key":"10.1016\/j.vaccine.2026.128989_bb0140","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1016\/j.vaccine.2023.07.061","article-title":"An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice","volume":"41","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"issue":"5076","key":"10.1016\/j.vaccine.2026.128989_bb0145","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/213612a0","article-title":"Adaptation and growth characteristics of influenza virus at 25 degrees c","volume":"213","author":"Maassab","year":"1967","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/infdis\/136.1.17","article-title":"Pilot studies on recombinant cold-adapted live type a and B influenza virus vaccines","volume":"136","author":"Davenport","year":"1977","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128989_bb0155","first-page":"554","article-title":"Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A\/Ann Arbor\/6\/60 (H2N2)","volume":"167","author":"Cox","year":"1988","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128989_bb0160","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1128\/jvi.62.2.488-495.1988","article-title":"Four viral genes independently contribute to attenuation of live influenza A\/Ann Arbor\/6\/60 (H2N2) cold-adapted reassortant virus vaccines","volume":"62","author":"Snyder","year":"1988","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128989_bb0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/(SICI)1099-1654(199910\/12)9:4<237::AID-RMV252>3.0.CO;2-G","article-title":"The development of live attenuated cold-adapted influenza virus vaccine for humans","volume":"9","author":"Maassab","year":"1999","journal-title":"Rev Med Virol"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128989_bb0170","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199805143382002","article-title":"The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children","volume":"338","author":"Belshe","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128989_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126653","article-title":"Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China","volume":"46","author":"Ai","year":"2025","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128989_bb0180","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038653","article-title":"Live attenuated cold-adapted influenza vaccines","volume":"11","author":"Subbarao","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128989_bb0185","article-title":"Impact of pre-existing immunity and age on antibody responses to live attenuated influenza vaccine","volume":"12","author":"Hoen","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128989_bb0190","article-title":"Immunogenicity as a predictor of influenza vaccine efficacy: a systematic review","volume":"13","author":"Martins","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41541-024-01011-x","article-title":"Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines","volume":"9","author":"Cort\u00e9s","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128989_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127918","article-title":"Characteristics of neuraminidase-specific immune responses in influenza vaccinated or naturally infected populations in Shenzhen, China","volume":"69","author":"Deng","year":"2026","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128989_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/v16030441","article-title":"Evaluation of vaccine immunogenicity\u2014correlates to real-world protection: influenza","volume":"16","author":"Laszlofy","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0210","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1038\/s41467-025-60714-4","article-title":"Increase in H5N1 vaccine antibodies confers cross-neutralization of highly pathogenic avian influenza H5N1","volume":"16","author":"Huang","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128989_bb0215","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4161\/hv.22908","article-title":"Correlates of protection to influenza virus, where do we go from here?","volume":"9","author":"Cox","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128989_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131531","article-title":"Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children","volume":"10","author":"Verschoor","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128989_bb0225","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jviromet.2013.07.032","article-title":"Serum antibodies against native and denaturated hemagglutinin glycoproteins detected by ELISA as correlates of protection after influenza vaccination in healthy vaccinees and in kidney transplant recipients","volume":"193","author":"Grund","year":"2013","journal-title":"J Virol Methods"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128989_bb0230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S0022172400064834","article-title":"Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis","volume":"93","author":"Al-Khayatt","year":"1984","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2026.128989_bb0235","author":"European Medicines Agency"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128989_bb0240","first-page":"6769","article-title":"Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?","volume":"84","author":"Lin","year":"2010"},{"key":"10.1016\/j.vaccine.2026.128989_bb0245","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/irv.12447","article-title":"The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells","volume":"11","author":"Lin","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128989_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12112358","article-title":"A modified novel validated high-throughput hemagglutinin inhibition assay using recombinant virus-like particles and human red blood cells for the objective evaluation of recombinant hemagglutinin nanoparticle seasonal influenza vaccine","volume":"12","author":"Vincent","year":"2024","journal-title":"Microorganisms"},{"issue":"39","key":"10.1016\/j.vaccine.2026.128989_bb0255","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1016\/j.vaccine.2020.07.022","article-title":"Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection","volume":"38","author":"Kim","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128989_bb0260","author":"U.S. Food & Drug"},{"key":"10.1016\/j.vaccine.2026.128989_bb0265","author":"Center for Drug Evaluation of NMPA"},{"key":"10.1016\/j.vaccine.2026.128989_bb0270","author":"FDA"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128989_bb0275","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00750-20","article-title":"Comparability of titers of antibodies against seasonal influenza virus strains as determined by hemagglutination inhibition and microneutralization assays","volume":"58","author":"Heeringa","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"sp1","key":"10.1016\/j.vaccine.2026.128989_bb0280","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1637\/11886-042718-Reg.1","article-title":"Are microneutralization and hemagglutination inhibition assays comparable? Serological results from influenza experimentally infected mallard ducks","volume":"63","author":"Segovia","year":"2019","journal-title":"Avian Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128989_bb0285","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2416779","article-title":"Efficacy, immunogenicity, and safety of modified mRNA influenza vaccine","volume":"393","author":"Fitz-Patrick","year":"2025","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128989_bb0290","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMc1803554","article-title":"Improved titers against influenza drift variants with a nanoparticle vaccine","volume":"378","author":"Shinde","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128989_bb0295","doi-asserted-by":"crossref","first-page":"e4278","DOI":"10.1093\/cid\/ciaa1673","article-title":"Induction of cross-reactive hemagglutination inhibiting antibody and polyfunctional CD4+ T-cell responses by a recombinant matrix-M-adjuvanted hemagglutinin nanoparticle influenza vaccine","volume":"73","author":"Shinde","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128989_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00161","article-title":"Pseudotype-based neutralization assays for influenza: a systematic analysis","volume":"6","author":"Carnell","year":"2015","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0305","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1038\/s41598-019-39276-1","article-title":"Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018","volume":"9","author":"Jorquera","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128989_bb0310","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70140","article-title":"Improved resolution of influenza vaccination responses with high-throughput live virus microneutralisation","volume":"19","author":"Adams","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.128989_bb0315","doi-asserted-by":"crossref","unstructured":"Aw, D.Z.H., et al., Serial passaging of seasonal H3N2 influenza a\/Singapore\/G2-31.1\/2014 virus in MDCK-SIAT1 cells and primary chick embryo cells generates HA D457G mutation and other variants in HA, NA, PB1, PB1-F2, and NS1. Int J Mol Sci, 2022. 23(20): p. 12408.","DOI":"10.3390\/ijms232012408"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128989_bb0320","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1128\/JVI.77.15.8418-8425.2003","article-title":"Overexpression of the \u03b1-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors","volume":"77","author":"Matrosovich","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128989_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661379","article-title":"Development of lentiviral vectors pseudotyped with influenza B hemagglutinins: application in vaccine immunogenicity, mAb potency, and sero-surveillance studies","volume":"12","author":"Ferrara","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0330","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-020-01472-1","article-title":"Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions","volume":"18","author":"Zheng","year":"2021","journal-title":"Virol J"},{"issue":"14","key":"10.1016\/j.vaccine.2026.128989_bb0335","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.2174\/1389201021666201104145006","article-title":"Design, synthesis and primary immunologic evaluation of M2e-CRM(197) conjugate as a universal influenza vaccine candidate","volume":"22","author":"Xu","year":"2021","journal-title":"Curr Pharm Biotechnol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128989_bb0340","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2011.11.024","article-title":"Noncontrolled trial of monovalent AS03-A-adjuvanted vaccine for 2009 pandemic influenza A(H1N1) in long-term Dialysis patients and transplant recipients","volume":"59","author":"Hansen","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.vaccine.2026.128989_bb0345","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jim.2015.04.009","article-title":"Validation of single radial haemolysis assay: a reliable method to measure antibodies against influenza viruses","volume":"422","author":"Trombetta","year":"2015","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128989_bb0350","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/irv.12591","article-title":"Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses","volume":"12","author":"Trombetta","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.128989_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.959379","article-title":"The role of cell-mediated immunity against influenza and its implications for vaccine evaluation","volume":"13","author":"Janssens","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128989_bb0360","article-title":"Application of humanized MHC transgenic mice in the screening of HLA-restricted T cell epitopes for influenza vaccines","volume":"13","author":"Wei","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128989_bb0365","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.immuni.2023.06.019","article-title":"Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids","volume":"56","author":"Kastenschmidt","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0370","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-67102-y","article-title":"Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial","volume":"17","author":"Rodr\u00edguez-Guilarte","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0375","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41541-026-01370-7","article-title":"An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial","volume":"11","author":"Henry","year":"2026","journal-title":"NPJ Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128989_bb0380","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70118","article-title":"Evaluating Bacillus Calmette-Gu\u00e9rin polysaccharide nucleic acid as an adjuvant for influenza vaccines in mice","volume":"19","author":"Yan","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.128989_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1381508","article-title":"Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response","volume":"15","author":"Mazunina","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128989_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483720","article-title":"The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice","volume":"15","author":"Di","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128989_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01166","article-title":"Non-sterilizing, infection-permissive vaccination with inactivated influenza virus vaccine reshapes subsequent virus infection-induced protective heterosubtypic immunity from cellular to humoral cross-reactive immune responses","volume":"11","author":"Choi","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128989_bb0400","article-title":"Enhanced immunogenicity of chicken H9N2 influenza inactivated vaccine through a novel dual-targeting fusion protein strategy","volume":"13","author":"Xu","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128989_bb0405","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2256422","article-title":"An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses","volume":"12","author":"Xiong","year":"2023","journal-title":"Emerg Microbes Infect"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128989_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12111275","article-title":"An optimised live attenuated influenza vaccine ferret efficacy model successfully translates H1N1 clinical data","volume":"12","author":"Schewe","year":"2024","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128989_bb0415","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10091528","article-title":"FLU-v, a broad-spectrum influenza vaccine, induces cross-reactive cellular immune responses in humans measured by dual IFN-\u03b3 and granzyme B ELISpot assay","volume":"10","author":"Oftung","year":"2022","journal-title":"Vaccines"},{"issue":"38","key":"10.1016\/j.vaccine.2026.128989_bb0420","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1016\/j.vaccine.2016.07.018","article-title":"High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses","volume":"34","author":"Kim","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128989_bb0425","article-title":"DNA vaccine encoding a modified hemagglutinin trimer of avian influenza A virus H5N8 protects mice from viral challenge","volume":"12","author":"Litvinova","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128989_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aag2152","article-title":"Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells","volume":"2","author":"Herati","year":"2017","journal-title":"Sci Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128989_bb0435","article-title":"Safety and immunogenicity study of a bivalent vaccine for combined prophylaxis of COVID-19 and influenza in non-human primates","volume":"12","author":"Stepanova","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128989_bb0440","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S2213-2600(22)00131-X","article-title":"Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"10","author":"Zhu","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2009.02.007","article-title":"Automation of the ELISpot assay for high-throughput detection of antigen-specific T-cell responses","volume":"344","author":"Almeida","year":"2009","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2026.128989_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.984642","article-title":"Harmonization and qualification of an IFN-\u03b3 enzyme-linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium","volume":"13","author":"Waerlop","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128989_bb0455","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1128\/CVI.00397-07","article-title":"Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children","volume":"15","author":"Forrest","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128989_bb0460","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1208\/s12248-025-01072-3","article-title":"IFN-\u03b3\/IL-2 double-color FluoroSpot assay for monitoring human primary T cell activation: validation, inter-laboratory comparison, and recommendations for clinical studies","volume":"27","author":"Mauthe","year":"2025","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0465","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10616-016-0037-4","article-title":"Towards standardized automated immunomonitoring: an automated ELISpot assay for safe and parallelized functionality analysis of immune cells","volume":"69","author":"Neubauer","year":"2017","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2026.128989_bb0470","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2172-6-17","article-title":"Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT","volume":"6","author":"Maecker","year":"2005","journal-title":"BMC Immunol"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128989_bb0475","doi-asserted-by":"crossref","first-page":"20824","DOI":"10.1021\/acsnano.5c03199","article-title":"Epitope-optimized influenza hemagglutinin nanoparticle vaccine provides broad cross-reactive immunity against H9N2 influenza virus","volume":"19","author":"Hao","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2026.128989_bb0480","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","article-title":"Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination","volume":"119","author":"Jansen","year":"2019","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2026.128989_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127361","article-title":"Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel","volume":"61","author":"Mishina","year":"2025","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128989_bb0490","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01107-25","article-title":"A single-dose intranasal immunization with a novel bat influenza a virus-vectored MERS vaccine provides effective protection against lethal MERS-CoV challenge","volume":"16","author":"Shi","year":"2025","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128989_bb0495","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.celrep.2014.06.052","article-title":"Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis","volume":"8","author":"Chung","year":"2014","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128989_bb0500","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/cyto.a.20613","article-title":"FATT-CTL assay for detection of antigen-specific cell-mediated cytotoxicity","volume":"73","author":"van Baalen","year":"2008","journal-title":"Cytometry A"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128989_bb0505","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038596","article-title":"Systems biological analysis of immune response to influenza vaccination","volume":"11","author":"Cortese","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2026.128989_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198396","article-title":"Evaluation of influenza A and B cold-adapted reassortant virus reproduction in trivalent live influenza vaccines","volume":"300","author":"Landgraf","year":"2021","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0515","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00109-014-1212-8","article-title":"Transcriptomic profiling facilitates classification of response to influenza challenge","volume":"93","author":"Davenport","year":"2015","journal-title":"J Mol Med (Berl)"},{"issue":"36","key":"10.1016\/j.vaccine.2026.128989_bb0520","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1016\/j.vaccine.2015.07.022","article-title":"Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-structure, function and species differences","volume":"33","author":"Pabst","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0525","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14760584.2023.2268724","article-title":"Mucosal vaccination: onward and upward","volume":"22","author":"Tsai","year":"2023","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128989_bb0530","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1439","article-title":"NALT- versus Peyer's-patch-mediated mucosal immunity","volume":"4","author":"Kiyono","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"8062","key":"10.1016\/j.vaccine.2026.128989_bb0535","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-025-08910-6","article-title":"Nasal vaccines for respiratory infections","volume":"641","author":"Kiyono","year":"2025","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128989_bb0540","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/irv.12664","article-title":"How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions","volume":"13","author":"Gianchecchi","year":"2019","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128989_bb0545","article-title":"Riboflavin as a mucosal adjuvant for nasal influenza vaccine","volume":"9","author":"Yin","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128989_bb0550","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140794","article-title":"A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity","volume":"131","author":"Matsuda","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2026.128989_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111710","article-title":"The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response","volume":"130","author":"Lian","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0560","article-title":"Influenza hemagglutinin nanoparticle vaccine elicits broadly neutralizing antibodies against structurally distinct domains of H3N2 HA","volume":"8","author":"Portnoff","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128989_bb0565","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2013.10.029","article-title":"Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants","volume":"60","author":"Chasela","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0570","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2189885","article-title":"The matrix-M\u2122 adjuvant: a critical component of vaccines for the 21(st) century","volume":"19","author":"Stertman","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128989_bb0575","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70614","article-title":"Novel mini-hemagglutinin subunit vaccine induces robust mucosal and systemic immunity and protection against a lethal challenge with the H1N1 and H5N1 influenza viruses in mice","volume":"97","author":"Wang","year":"2025","journal-title":"J Med Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128989_bb0580","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1039\/D4NH00287C","article-title":"Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice","volume":"9","author":"Kim","year":"2024","journal-title":"Nanoscale Horiz"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128989_bb0585","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1038\/s41467-025-64686-3","article-title":"An intranasal adjuvanted, recombinant influenza A\/H5 vaccine primes against diverse H5N1 clades: a phase I trial","volume":"16","author":"Deming","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128989_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112721","article-title":"Mucosal boosting increases protective efficacy of an influenza vaccine in mice","volume":"28","author":"Wang","year":"2025","journal-title":"iScience"},{"issue":"847","key":"10.1016\/j.vaccine.2026.128989_bb0595","doi-asserted-by":"crossref","first-page":"eadz8439","DOI":"10.1126\/scitranslmed.adz8439","article-title":"Local B-cell immunity and durable memory following live-attenuated influenza intranasal vaccination of humans","volume":"18","author":"Stacey","year":"2026","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128989_bb0600","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.vaccine.2020.02.024","article-title":"Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV","volume":"38","author":"Hoschler","year":"2020","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128989_bb0605","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/infdis\/jiz593","article-title":"Modified vaccinia Ankara-vectored vaccine expressing nucleoprotein and matrix protein 1 (M1) activates mucosal M1-specific T-cell immunity and tissue-resident memory T cells in human nasopharynx-associated lymphoid tissue","volume":"222","author":"Puksuriwong","year":"2020","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128989_bb0615","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1750-2659.2011.00330.x","article-title":"Induction and maintenance of anti-influenza antigen-specific nasal secretory IgA levels and serum IgG levels after influenza infection in adults","volume":"6","author":"Fujimoto","year":"2012","journal-title":"Influenza Other Respir Viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128989_bb0620","article-title":"A phase 1 randomized placebo-controlled study to assess the safety, immunogenicity and genetic stability of a new potential pandemic H7N9 live attenuated influenza vaccine in healthy adults","volume":"8","author":"Kiseleva","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128989_bb0625","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70645","article-title":"Detection of anti-SARS-CoV-2 mucosal immunoglobulin a in clinical saliva samples after a dose of Novavax COVID-19 vaccine","volume":"97","author":"Zhu","year":"2025","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2026.128989_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2017.06.008","article-title":"Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity","volume":"449","author":"de Silva","year":"2017","journal-title":"J Immunol Methods"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128989_bb0635","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70014","article-title":"Inno4Vac workshop report part 1: controlled human influenza virus infection model (CHIVIM) strain selection and immune assays for CHIVIM studies, November 2021, MHRA, UK","volume":"18","author":"Waldock","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"issue":"Supplement_1","key":"10.1016\/j.vaccine.2026.128989_bb0640","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf695.879","article-title":"P-666. Human challenge models using current clinical strains of influenza, RSV, hMPV, and SARS-CoV-2 omicron","volume":"13","author":"Noulin","year":"2026","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128989_bb0645","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"Supplement_2","key":"10.1016\/j.vaccine.2026.128989_bb0650","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1093\/cid\/ciaf377","article-title":"Historical advances in clinical trial design and expanding representation as the new frontier for innovation","volume":"81","author":"Jano","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128989_bb0655","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092153","article-title":"Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses","volume":"9","author":"Skowronski","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128989_bb0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010875","article-title":"Egg-adaptive mutations of human influenza H3N2 virus are contingent on natural evolution","volume":"18","author":"Liang","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2026.128989_bb0665","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2189885","article-title":"The matrix-M\u2122 adjuvant: a critical component of vaccines for the 21st century","volume":"19","author":"Stertman","year":"2023","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600798X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600798X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:20:59Z","timestamp":1788297659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600798X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":132,"alternative-id":["S0264410X2600798X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128989","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in clinical immunogenicity evaluation of influenza vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128989"}}